Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 9/20 | 0.64 |
| ▸ | RARA | P10276 | 1/20 | 0.58 |
| ▸ | RARB | P10826 | 1/20 | 0.58 |
| ▸ | RARG | P13631 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.42 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2664865 | 0.86 | GCK (0.65) | GCKRARARARBRARGMEN1 | |
| SCHEMBL2664598 | 0.84 | GCK (0.61) | GCKRARARARBRARGMEN1 | |
| SCHEMBL14191882 | 0.81 | GCK (0.59) | GCKRARARARBRARGMEN1 | |
| SCHEMBL2664601 | 0.81 | GCK (0.64) | GCKRARARARBRARGMEN1 | |
| SCHEMBL2664595 | 0.81 | GCK (0.58) | GCKRARARARBRARGKMT2A | |
| SCHEMBL2664596 | 0.80 | GCK (0.57) | GCKRARARARBRARGMEN1 | |
| SCHEMBL1792656 | 0.79 | GCK (0.57) | GCKRARARARBRARGMEN1 | |
| SCHEMBL2664599 | 0.79 | GCK (0.56) | GCKRARARARBRARGMEN1 | |
| SCHEMBL2664640 | 0.79 | GCK (0.61) | GCKRARARARBRARGMEN1 | |
| SCHEMBL14217544 | 0.79 | GCK (0.56) | GCKRARARARBRARGMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951830-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2011-05-31 | — | — | US | disclosed |
| US-7951830-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2011-05-31 | — | — | US | disclosed |
| US-7951830-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2011-05-31 | — | — | US | disclosed |
| US-20090227592-A1 | COMPOUNDS EFFECTING GLUCOKINASE | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | disclosed |
| US-20090227592-A1 | COMPOUNDS EFFECTING GLUCOKINASE | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | disclosed |
| US-20090227592-A1 | COMPOUNDS EFFECTING GLUCOKINASE | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | disclosed |
| US-7524957-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2009-04-28 | — | — | US | disclosed |
| US-7524957-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2009-04-28 | — | — | US | disclosed |
| US-7524957-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2009-04-28 | — | — | US | disclosed |
| EP-1987831-A1 | COMPOUNDS EFFECTING GLUCOKINASE | AstraZeneca AB (SE) | 2008-11-05 | — | — | EP | disclosed |
| EP-1674097-A1 | Compounds effecting glucokinase | AstraZeneca AB (SE) | 2006-06-28 | — | — | EP | disclosed |
| EP-1669068-A1 | Compounds effecting Glucokinase | AstraZeneca AB (SE) | 2006-06-14 | — | — | EP | disclosed |
| EP-1669069-A1 | Compounds effecting glukokinase | AstraZeneca AB (SE) | 2006-06-14 | — | — | EP | disclosed |
| EP-1661569-A1 | Compounds effecting glucokinase | AstraZeneca AB (SE) | 2006-05-31 | — | — | EP | disclosed |
| EP-1661563-A1 | Compound effecting Glucokinase | AstraZeneca AB (SE) | 2006-05-31 | — | — | EP | disclosed |
| EP-1661567-A1 | Compounds effecting Glucokinase | AstraZeneca AB (SE) | 2006-05-31 | — | — | EP | disclosed |
| EP-1420784-B1 | COMPOUNDS EFFECTING GLUCOKINASE | ASTRAZENECA AB (SE) | 2006-04-19 | — | — | EP | disclosed |
| EP-1568367-A1 | Compounds effecting glucokinase | AstraZeneca AB (SE) | 2005-08-31 | — | — | EP | disclosed |
| EP-1529530-A1 | Compounds affecting glucokinase | AstraZeneca AB (SE) | 2005-05-11 | — | — | EP | disclosed |
| US-20050080106-A1 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080106-A1 | Compounds effecting glucokinase | GCKR, GCK, SLC5A2 | GCK 2/4885RARA 3925/4885RARB 3902/4885 |
| US-20090227592-A1 | COMPOUNDS EFFECTING GLUCOKINASE | GCKR, GCK, SLC5A2 | GCK 2/4885RARA 3925/4885RARB 3902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.